IPSC

Overview of IPS cell prospects for clinical impact

IPS-cell-clincial-trials-map

IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for …

Overview of IPS cell prospects for clinical impact Read More »

Regenerative medicine recommended reads including $191 million to researcher

Mark-Pennesi-CRISPR-regenerative-medicine-eye

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as …

Regenerative medicine recommended reads including $191 million to researcher Read More »

Recent stem cell news: vision, brain organoids, & lab meat

human-corneal-anatomy2

365 days a year, 24 hours a day stem cells are growing in labs around the world, providing a never-ending stream of data and products, with real hope, good news, and lots of surprises. You can see some past examples of good news in the stem cell and regenerative medicine field highlighted on The Niche here. …

Recent stem cell news: vision, brain organoids, & lab meat Read More »

3X recent stem cell & regenerative medicine good news

Stem cells spina bifida

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect …

3X recent stem cell & regenerative medicine good news Read More »

Japan conditionally approves new IPS cell-based heart study

Yoshiki-Sawa-IPS-cells-stem-cells-heart-diseease

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work …

Japan conditionally approves new IPS cell-based heart study Read More »

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective

Agnes-Soos

By Agnes Soos Amid the hustle and bustle of downtown Boston, nearly four thousand researchers and exhibitors gathered for the 15th Annual ISSCR Meeting. With presentations from over thirty plenary lectures, and dozens of others featured in concurrent sessions and the daily Innovation Showcases, there definitely was no shortage of exciting research to discover and …

Highlights of ISSCR2017 – A Biomedical Engineer’s Perspective Read More »

Takeaways from new Yamanaka (山中伸弥) stem cell interview

Dr.-ShinyaYamanaka

Shinya Yamanaka is one of my favorite fellow scientists. His research is creative and rigorous along with having huge clinical implications. At the same time, Dr. Yamanaka sees the big picture and he’s very open about talking about real life as a scientist. I really appreciate both levels. In the past I interviewed him for …

Takeaways from new Yamanaka (山中伸弥) stem cell interview Read More »

Masayo Takahashi (高橋 政代) on IPSC Trial for Vision

Monkey-stem-cell-RPEs

Masayo Takahashi (高橋 政代) on IPSC Trial for Macular Degeneration By Michael Cea Stem Cell Analyst & Advocate (editor’s note: piece was originally posted on Michael’s blog here; follow Michael on Twitter @msemporda) Having followed closely the developments in programs using pluripotent based therapeutics I was fortunate during ISSCR2015 to have the opportunity to sit down with …

Masayo Takahashi (高橋 政代) on IPSC Trial for Vision Read More »

Was Fujifilm CDI acquisition a good move by the companies?

Fujifilm-Logo

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did …

Was Fujifilm CDI acquisition a good move by the companies? Read More »